Open Access. Powered by Scholars. Published by Universities.®
- Keyword
-
- Animal cell (1)
- Animal experiment (1)
- Animal model (1)
- Animal tissue (1)
- Antibody titer (1)
-
- Antigenic variation (1)
- Article (1)
- Borrelia burgdorferi (1)
- Controlled study (1)
- Female (1)
- Hendra virus (1)
- Humoral immunity (1)
- Immune response (1)
- Inactivated vaccines (1)
- Long term care (1)
- Lyme disease (1)
- Male (1)
- Mouse (1)
- Nonhuman (1)
- Rabies virus (1)
- Tick (1)
- Vaccine immunogenicity (1)
- Vaccines (1)
- Virus particle (1)
Articles 1 - 2 of 2
Full-Text Articles in Complex Mixtures
Rabies Virus-Vectored Lyme Disease Vaccine Provides Long-Term Protection Against Tick-Transmitted Borrelia Burgdorferi, Shantel Rios, Bibek Bhattachan, Christoph Wirblich, Anisha Chandwani, Kruthi Vavilikolanu, Jacob F. Myers, Chrysoula Kitsou, Utpal Pal, Matthias J. Schnell
Rabies Virus-Vectored Lyme Disease Vaccine Provides Long-Term Protection Against Tick-Transmitted Borrelia Burgdorferi, Shantel Rios, Bibek Bhattachan, Christoph Wirblich, Anisha Chandwani, Kruthi Vavilikolanu, Jacob F. Myers, Chrysoula Kitsou, Utpal Pal, Matthias J. Schnell
Department of Microbiology and Immunology Faculty Papers
Lyme disease (LD) cases have doubled globally. LD is a tick-borne illness caused by the Borrelia burgdorferi sensu lato (Bb). If untreated, Bb can disseminate to distal organs, causing carditis, arthritis, and meningitis. Currently, no FDA-approved human LD vaccine exists on the market. This study used two approaches to incorporate OspA into the rabies virus (RABV) vaccine vector. We used the RABV-glycoprotein tail (RVG tail) and the Hendra virus (HeV) glycoprotein tail (HVG tail) to incorporate OspA, creating BNSP333-OspA-RVG and BNSP333-OspA-HVG, respectively. Both vaccines produced type-1 biased anti-OspA antibodies, but only BNSP333-OspA-HVG induced neutralizing antibodies and protected against Bb infection. …
Inactivated Rabies-Based Lassa Fever Virus Vaccine Candidate Lassarab Protects Nonhuman Primates From Lethal Disease, Gabrielle Scher, Catherine Yankowski, Drishya Kurup, Nicole Josleyn, Eric Wilkinson, Jay Wells, Jesse Steffens, Ginger Lynn, Sean Vantongeren, Xiankun Zeng, Nancy Twenhafel, Kathleen Cashman, Matthias Schnell
Inactivated Rabies-Based Lassa Fever Virus Vaccine Candidate Lassarab Protects Nonhuman Primates From Lethal Disease, Gabrielle Scher, Catherine Yankowski, Drishya Kurup, Nicole Josleyn, Eric Wilkinson, Jay Wells, Jesse Steffens, Ginger Lynn, Sean Vantongeren, Xiankun Zeng, Nancy Twenhafel, Kathleen Cashman, Matthias Schnell
Department of Microbiology and Immunology Faculty Papers
Lassa fever virus (LASV), a member of the Arenavirus family, is the etiological agent of Lassa fever, a severe hemorrhagic disease that causes considerable morbidity and mortality in the endemic areas of West Africa. LASV is a rodent-borne CDC Tier One biological threat agent and is on the World Health Organization's (WHO) Priority Pathogen list. Currently, no FDA-licensed vaccines or specific therapeutics are available. Here, we describe the efficacy of a deactivated rabies virus (RABV)-based vaccine encoding the glycoprotein precursor (GPC) of LASV (LASSARAB). Nonhuman primates (NHPs) were administered a two-dose regimen of LASSARAB or an irrelevant RABV-based vaccine to …